Puma Biotechnology, Inc.
US ˙ NasdaqGS ˙ US74587V1070

SecurityPBYI / Puma Biotechnology, Inc.
InstitutionMackenzie Financial Corp
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Mackenzie Financial Corp closes position in PBYI / Puma Biotechnology, Inc.

On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 0 shares of Puma Biotechnology, Inc. (US:PBYI) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 160,973 shares of Puma Biotechnology, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -100.00 0
2026-02-18 2025-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 160,973 -14,237 -8.13 966 3.76 0.0011
2025-11-13 2025-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 175,210 -32,381 -15.60 930 30.62 0.0011
2025-08-13 2025-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 207,591 49,878 31.63 712 52.79 0.0009
2025-05-07 2025-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 157,713 79,060 100.52 467 94.98 0.0007
2025-05-02 2024-12-31 13F/A-2 PUMA BIOTECHNOLOGY COM 74587V107 78,653 78,653 240 0.0003
2025-02-20 2024-12-31 13F/A-1 PUMA BIOTECHNOLOGY COM 74587V107 78,653 78,653 240 0.0003
2025-02-14 2024-12-31 13F Puma Biotechnology Common Stock 74587V107 78,653 78,653 238 0.0003
2022-10-07 2022-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -10,090 -100.00 0 -100.00
2022-08-10 2022-06-30 13F PUMA BIOTECHNOLOGY COM 74587V107 10,090 -2,074 -17.05 29 -17.14 0.0000
2022-05-13 2022-03-31 13F PUMA BIOTECHNOLOGY COM 74587V107 12,164 12,164 35 0.0000
2021-02-10 2020-12-31 13F PUMA BIOTECHNOLOGY COM 74587V107 0 -38,740 -100.00 0 -100.00
2020-11-13 2020-09-30 13F PUMA BIOTECHNOLOGY COM 74587V107 38,740 38,740 391 0.0010
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.